Zenith Epigenetics
  • About
  • Science & Epigenetics
  • Programs
  • Newsroom
  • Contact
  • Connect
    Email
    info@zenithepigenetics.com
    Call
    1 (587) 390-7865
    Share
  • FAQ
Newsroom
  • News Releases
  • Presentations & Events
  • SEDAR Filings

News Releases

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Zenith Announces Voting Results from the 2020 Annual and Special Meeting of Shareholders
December 22, 2020
Zenith Files Notice of Annual and Special Meeting of Shareholders
November 20, 2020
Zenith Confirms Interim Filings on SEDAR
October 28, 2020
Zenith Provides Update Regarding Extension of its Filing Calendar
October 9, 2020
Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications
October 5, 2020
Zenith Provides Update Regarding Extension of its Filing Calendar
October 1, 2020
Zenith Provides Update Regarding Extension of its Filing Calendar
September 17, 2020
Zenith Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
August 26, 2020
Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs
July 29, 2020
Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment
June 16, 2020
Zenith Epigenetics Receives US$5 Million Milestone Payment from Newsoara
January 7, 2020

About

  • Overview
  • Management
  • Board of Directors

Science & Epigenetics

  • What is Epigenetics?
  • BET Inhibitors & Oncology
    • Resistance & Combo Therapy
  • BET Inhibitor Platform
    • Covalent BET Inhibitors
    • Translational Medicine
  • Publications & Posters

Programs

  • Oncology Pipeline
    • Prostate Cancer
    • Breast Cancer
    • Ovarian Cancer
    • Lung Cancer
    • Other Solid Tumor Cancers
  • Partnerships & Collaborations

Newsroom

  • News Releases
  • Presentations & Events
  • SEDAR Filings

Contact

  • Contact
  • Careers
  • Shareholder FAQ

© 2025 zenithepigenetics | Legal | Privacy

Bookmark and Share